Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-12-18
2009-11-03
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263400, C544S277000, C564S321000, C564S503000
Reexamination Certificate
active
07612079
ABSTRACT:
The present invention relates to compounds of formula Ior a pharmaceutically acceptable salt thereof whereinR2is 2-hydroxymethylpyrrolidin-1-yl, or NHCH(R4)CH(R3)OH, wherein R3is hydrogen or methyl and R4is methyl, ethyl or isopropyl;R6is 3-nitrophenylamino, 3,4-dimethoxybenzylamino, 3-iodobenzyl-amino, pyrid-2-yl-methylamino, pyrid-4-yl-methylamino or indan-5-amino;R9is isopropyl or cyclopentanyl.In a further aspect, the invention relates to pharmaceutical compositions comprising said compounds, and the use thereof in treating antiproliferative disorders and or viral disorders.
REFERENCES:
patent: 5688774 (1997-11-01), Jacobson et al.
patent: 6110923 (2000-08-01), Ely
patent: 6255485 (2001-07-01), Gray et al.
patent: 6316456 (2001-11-01), Meijer et al.
patent: 6552192 (2003-04-01), Hanus et al.
patent: 6573044 (2003-06-01), Gray et al.
patent: 6790958 (2004-09-01), Lum et al.
patent: 6949644 (2005-09-01), Ding et al.
patent: 2003/0191312 (2003-10-01), Ding et al.
patent: 2003/0229105 (2003-12-01), Kashanchi
patent: 2005/0256142 (2005-11-01), Fischer et al.
patent: 2006/0183760 (2006-08-01), Fischer et al.
patent: 665229 (1999-11-01), None
patent: 07-075798 (1995-03-01), None
patent: WO 90/09178 (1990-08-01), None
patent: WO 93/17020 (1993-09-01), None
patent: WO 93/17020 (1993-09-01), None
patent: WO 97/16452 (1997-05-01), None
patent: WO 97/20842 (1997-06-01), None
patent: WO 98/16528 (1998-04-01), None
patent: WO 99/07705 (1999-02-01), None
patent: WO 99/34018 (1999-07-01), None
patent: WO 99/43676 (1999-09-01), None
patent: WO 00/44750 (2000-08-01), None
patent: WO 00/55161 (2000-09-01), None
Prerna Diwan et al., J Virol. Sep. 2004; 78(17): 9352-9365.
Thais M. Sielecki, J. Med. Chem. 2000; 43(1) pp. 1-18.
Voskoglou-Nomikos et al. Clin. Cancer Res. 9(11):4227-39, 2003.
Abraham et al. “Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.”Biol. Cell. 1995;83(2-3):105-20.
Chang et al. “Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.”Chem. Biol. Jun. 1999;6(6):361-75.
De Azevedo et al. “Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.”Eur. J. Biochem. Jan. 15, 1997;243(1-2):518-26.
Ducrot et al. “3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.”J. Med. Chem. Nov. 2, 2000;43(22):4098-108.
Fukatsu et al. “Synthesis of “reversed” nucleosides of some purine and pyrimidine bases.”Bulletin of the Chemical Society of Japan1973;46:3165-8.
Giocanti et al. “In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor.”Ann. N.Y. Acad. Sci. 1999;886:180-2.
Gray, et al. “Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.”Science. Jul. 24, 1998;281(5376):533-8.
Gray, et al. “ATP-site directed inhibitors of cyclin-dependent kinases.”Curr. Med. Chem. Sep. 1999;6(9):859-75.
Havli{hacek over (c)}ek et al. “Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.”J. Med. Chem. 1997;40(4):408-12.
Holy “Synthesis of enantiomeric N-(3-hydroxy-2-phosphono-methoxypropyl) derivatives of purine and pyrimidine bases.”Collect. Czech. Chem. Commun. 1993;58:649-74.
Imbach et al. “2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.”Bioorg. Med. Chem. Lett. Jan. 4, 1999;9(1):91-6.
Legraverend et al. “Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.”Bioorg. Med. Chem. Lett. Apr. 7, 1998;8(7):793-8.
Legraverand et al. “Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.”Bioorg. Med. Chem. 1999;7(7):1281-93.
Meijer et al. “Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-depenedent kinases cdc2, cdk2 and cdk5.”Eur. J. Biochem. 1997;243(1-2):527-36.
Oh et al. “Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.”Arch. Pharm. (Weinheim). Jun. 1999;332(6):187-90.
Rudolph et al. “Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis.”EMBO J. Jun. 17, 1996;15(12):3065-76.
Schow et al. “Synthesis and activity of 2,6,9-trisubstituted purines.”Bioorg. Med. Chem. Lett. 1997;7(21):2697-702.
Tao et al. “Inhibitors of cytokinin metabolism III. The inhibition of cytokininN-glucosylation in radish cotyledons.”J. Plant Growth Regul. 1991;10:179-85.
Veeranne “Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18.”Neurochem. Res. May 1996;21(5):629-36.
Vesely et al. “Inhibition of cyclin-dependent kinases by purine analogues.”Eur. J. Biochem. Sep. 1, 1994;224(2):771-86.
Fischer Peter Martin
Jarman Mike
McDonald Ted
Nutley Bernard
Raynaud Florence
Berch Mark L
Cancer Research Technology Limited
Cyclacel Limited
Kanik Cynthia L.
Lahive & Cockfield LLP
LandOfFree
2,6,9-substituted purine derivatives and their use in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,6,9-substituted purine derivatives and their use in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,6,9-substituted purine derivatives and their use in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142030